San Diego Biotechnology Network’s Post

SDBN Trending News: Candid Therapeutics unwraps three new collaborations to discover and develop T-cell engager antibodies https://lnkd.in/gjbx3FzK Candid Therapeutics, a new San Diego biotech bent on becoming a leader in the emerging T-cell engager space, has unwrapped three new research collaborations focusing on autoimmune diseases. Candid will partner with EpimAb Biotherapeutics, Nona [...]

AbbVie to Buy Nimble Therapeutics for $200 Million US #biopharma AbbVie has signed an agreement to acquire US #biotechnology company Nimble Therapeutics, including its lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis and a pipeline of other novel oral peptide candidates with potential across several autoimmune diseases. Additionally, AbbVie will acquire Nimble's peptide synthesis, screening, and optimization platform, which uses proprietary technology for the rapid discovery and optimization of peptide candidates for a range of targets. "The addition of Nimble's pipeline to AbbVie's existing pipeline, combined with our deep clinical and translational expertise in immunology, represents an important growth opportunity," said Jonathon Sedgwick, AbbVie’s senior vice president and global head of discovery research. "Together, AbbVie and Nimble have the potential to help address the significant unmet medical need for people living with #autoimmune diseases." Read more on #CMI online: https://lnkd.in/ebbvGtnB

🔬 The concept of immune related Adverse Outcome Pathways 🔬   Bringing a new generation of potent immunomodulatory biotherapeutics like cytokines, antibodies and cell therapeutics to the market requires novel development approaches. These products are highly human specific and have lead to major challenges for preclinical safety and efficacy testing. To deal with this challenges #ImSAVAR has introduced the concept of Adverse Outcome Pathways to describe all safety relevant functions of new therapeutic agents. In this special issue, we showcase examples using IL-2 and CAR T-cell therapeutics. ImSAVAR’s vision is to use an AOP-guided process for the systematic and holistic regulatory development of immunomodulatory biopharmaceuticals. It aims at establishing an overarching framework for regulatory decision making. Read our full article here: https://lnkd.in/efsrYvmV Armin Braun Susann Dehmel Fraunhofer ITEM

Rise Therapeutics Receives FDA IND Clearance To Initiate Clinical Testing of R-5780 in Cancer https://lnkd.in/g6i9NJ3p UF startup Rise Therapeutics, a biotechnology company engaged in developing novel oral Immunotherapeutics, announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a cancer Phase [...]

Are molecular glue degraders having their moment? In BioSpace, Mark Foundation CEO Ryan Schoenfeld shares why he thinks we’re at an inflection point for this promising drug class.

🔬 The concept of immune related Adverse Outcome Pathways 🔬 Bringing a new generation of potent immunomodulatory biotherapeutics like cytokines, antibodies and cell therapeutics to the market requires novel development approaches. These products are highly human specific and have lead to major challenges for preclinical safety and efficacy testing. To deal with this challenges imSAVAR has introduced the concept of Adverse Outcome Pathways to describe all safety relevant functions of new therapeutic agents. In this special issue, we showcase examples using IL-2 and CAR T-cell therapeutics. ImSAVAR’s vision is to use an AOP-guided process for the systematic and holistic regulatory development of immunomodulatory biopharmaceuticals. It aims at establishing an overarching framework for regulatory decision making. Please find the whole issue here 🌐 https://lnkd.in/efsrYvmV Armin Braun Susann Dehmel

One of the biggest biotech investment events of the year, J.P. Morgan’s annual Healthcare Conference, took place this week! 🧬 As part of the event, BioIndustry Association (BIA) and the United Kingdom's Department for Business and Trade (DBT) have curated the #JPM2025 news roundup, bringing together biotech headlines from the conference in one convenient place. We are delighted that BIA has included our latest company news in this roundup, announcing further in vivo validation in our first-in-class approach against multiple tumours following a successful mouse trial. Key results from our in vivo mouse colorectal cancer model study include: ✅ A 60% life extension, indicating clear efficacy and dose response. ✅ An acceptable safety profile, paving the way for further optimisation. These promising findings have led to an expanded mouse study which is currently underway and already showing further positive progress. Read more about this exciting development here: https://lnkd.in/eDEGMUHt #cancerresearch #drugdiscovery #clinicaltrials #biotechnology #pharmaceutical

Thoughts on this? >> Hornet Therapeutics revives former Kyowa Kirin cancer drug for Epstein-Barr-driven diseases >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #productmarketing #biotech #healthcare

I enjoyed speaking with Kate Goodwin from BioSpace last week about the rising interest in molecular glue degraders (MDG) and their potential to treat cancer and other diseases that were once considered untreatable. The level of investment this year alone from major pharmaceutical companies like Novartis, Biogen, Takeda and Novo Nordisk signals optimism for the promise MGDs hold in creating more precise, effective, and safe therapeutics. Read the full interview here: https://lnkd.in/eCueRFPf.

Thoughts on this? >> Hornet Therapeutics revives former Kyowa Kirin cancer drug for Epstein-Barr-driven diseases >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #productmarketing #pharma #healthcare #biotech